MDMA/FDA meeting
This article was originally published in The Gray Sheet
Executive Summary
Medical Device Manufacturers Association President Larry Holden and Director of Federal Affairs Mark Leahey plan to meet with FDA Acting Commissioner Lester Crawford and CDRH Director David Feigal June 4. Among probable discussion topics are a device user fee proposal negotiated by trade group AdvaMed and FDA. The proposal was recently excluded from bioterrorism legislation but could still be reconsidered by Congress this session along with Greenwood/Eshoo device reforms (1"The Gray Sheet" May 27, 2002, p. 3)...
You may also be interested in...
Kennedy To Industry: User Fees Still In Play If Third Party Sits This One Out
Industry supporters of medical device user fees are assuming a formidable challenge by linking the legislative proposal with the "Medical Device Amendments of 2001" (HR 3580), introduced by Reps. Jim Greenwood (R-Penn.) and Anna Eshoo (D-Calif.)
FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Need a specific report? 1000+ reports available
Buy Reports